Kromek Group (KMK) CMD Q&A 2025 summary

Strategic direction and growth pillars

• Focused on two main growth pillars: advanced imaging and CBRN detection, targeting high-growth markets with a robust IP-rich technology platform and high barriers to entry.

• Advanced imaging leverages CZT technology for medical, security, and industrial applications, with a $320 million addressable market by 2030 and strong OEM relationships, especially in Asia and China.

• CBRN detection benefits from increased global defense spending, established frameworks in the UK and US, and a strategy to expand distributor networks and sales teams, prioritizing organic growth and disciplined M&A.

• Biosecurity programs in the US and UK are progressing toward commercialization, with future opportunities in agriculture and early-stage strategic partnership discussions.

• Capital allocation prioritizes organic growth, operational efficiency, and maintaining a sustainable balance sheet.

Financial guidance and performance

• FY25 revenue expected to exceed £26m, with over 30% growth and first positive PBT (>£1.8m), marking a transformational year.

• Midterm targets set at >£60 million revenue, 30–35% EBITDA within five years, and a 20% CAGR, supported by strong contract wins and a positive profit trajectory.

• Gross margin improved from 46.7% in FY22 to 55.2% in FY24, with product mix (notably the Siemens contract) expected to further increase margins.

• Achieved PBT profitability for the first time, reduced debt to £500,000, and expect continued revenue growth in FY2026 and beyond.

• Cash generation is improving, with no anticipated need for further equity raises; 2025 is described as a transformational year.

Market opportunities and business model

• Group total addressable market exceeds $1.4bn, with advanced imaging TAM at $400m+ and CBRN at ~$1bn.

• Only commercial supplier of CZT detectors for medical imaging, with no meaningful competition in the core market; alternative technologies are not seen as a threat.

• Business models leverage long-term contracts, enablement agreements, and product sales, with minimal capex and strong IP protection.

• M&A framework targets profitable, synergistic acquisitions to broaden CBRN footprint and product range, but is not required to achieve the £60 million revenue target.

• Regional growth prioritized in the UK, US, Europe, and Asia, with Asia (excluding China and India) seen as a key opportunity for CBRN.